Literature DB >> 16598823

Skewed expression of natural-killer (NK)-associated antigens on lymphoproliferations of large granular lymphocytes (LGL).

Lars Fischer1, Michael Hummel, Thomas Burmeister, Stefan Schwartz, Eckhard Thiel.   

Abstract

Killer-immunoglobulin-like receptors (KIR) or C-type lectin-like receptors are heterogeneously expressed on NK cells and small subsets of T cells and might provide a new diagnostic tool for LGL lymphoproliferations (LGLL). We investigated the diagnostic impact of these cell surface molecules in T- and NK-type LGLL. Using three-color flow cytometry we examined the expression patterns of KIR (CD158a/b/e/i), CD85j, lectin-like receptors (CD94, CD161, NKG2A/D) and natural cytotoxicity receptors (NKp30/44/46) in 13 patients with LGLL (10 T-, 3 NK-LGLL) and compared them to those of the corresponding lymphocyte subsets in 20 control subjects. The presence of clonal TCR-gamma rearrangements and of Epstein Barr virus- (EBV) DNA were evaluated by PCR. All patients exhibited an altered expression of NK-associated markers. KIR were either lacking (6/13) or overexpressed (7/13). CD94 expression was significantly higher in all LGLL. NKG2A expression was significantly higher in NK-LGLL. Absence or overexpression was observed for NKG2A in T-LGLL and CD161 in most T/NK-LGLL. In NK-LGLL expression of NKp30 and NKp46 was significantly decreased, whereas CD85j was overexpressed. We consistently found a skewed expression pattern of novel NK markers as a pathological feature of LGLL. These antigens should be included in the diagnostic workup of this rare disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598823     DOI: 10.1002/hon.777

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  7 in total

1.  CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy.

Authors:  Lars Fischer; Nicola Gökbuget; Stefan Schwartz; Thomas Burmeister; Harald Rieder; Monika Brüggemann; Dieter Hoelzer; Eckhard Thiel
Journal:  Haematologica       Date:  2008-12-23       Impact factor: 9.941

2.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

3.  Chronic NK lymphocytosis identified by a distinct immunophenotypic pattern.

Authors:  Hae Tha Mya; Yeh Ching Linn; Lay Cheng Lim; Heng Joo Ng
Journal:  Int J Hematol       Date:  2016-09-30       Impact factor: 2.490

Review 4.  The pathogenesis and treatment of large granular lymphocyte leukemia.

Authors:  Steven Nathaniel Steinway; Francis LeBlanc; Thomas P Loughran
Journal:  Blood Rev       Date:  2014-03-07       Impact factor: 8.250

5.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

Review 6.  Large granular lymphocytic leukemia: a brief review.

Authors:  Ekta Rahul; Aparna Ningombam; Shreyam Acharya; Pranay Tanwar; Amar Ranjan; Anita Chopra
Journal:  Am J Blood Res       Date:  2022-02-15

7.  Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality.

Authors:  Paloma Bárcena; María Jara-Acevedo; María Dolores Tabernero; Antonio López; María Luz Sánchez; Andrés C García-Montero; Noemí Muñoz-García; María Belén Vidriales; Artur Paiva; Quentin Lecrevisse; Margarida Lima; Anton W Langerak; Sebastian Böttcher; Jacques J M van Dongen; Alberto Orfao; Julia Almeida
Journal:  Oncotarget       Date:  2015-12-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.